Ethic Inc. Reduces Position in Zimmer Biomet Holdings, Inc. $ZBH

Ethic Inc. lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,208 shares of the medical equipment provider’s stock after selling 527 shares during the period. Ethic Inc.’s holdings in Zimmer Biomet were worth $568,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Greatmark Investment Partners Inc. boosted its stake in Zimmer Biomet by 4.0% during the 2nd quarter. Greatmark Investment Partners Inc. now owns 21,540 shares of the medical equipment provider’s stock valued at $1,965,000 after purchasing an additional 825 shares during the period. Brookstone Capital Management lifted its stake in Zimmer Biomet by 7.5% during the second quarter. Brookstone Capital Management now owns 9,227 shares of the medical equipment provider’s stock valued at $842,000 after purchasing an additional 644 shares during the last quarter. Citizens & Northern Corp lifted its position in shares of Zimmer Biomet by 2.3% in the 2nd quarter. Citizens & Northern Corp now owns 12,908 shares of the medical equipment provider’s stock valued at $1,177,000 after acquiring an additional 292 shares in the last quarter. FNY Investment Advisers LLC lifted its position in shares of Zimmer Biomet by 72.5% in the 2nd quarter. FNY Investment Advisers LLC now owns 690 shares of the medical equipment provider’s stock valued at $62,000 after acquiring an additional 290 shares in the last quarter. Finally, Studio Investment Management LLC increased its stake in Zimmer Biomet by 1.2% in the 2nd quarter. Studio Investment Management LLC now owns 18,385 shares of the medical equipment provider’s stock valued at $1,681,000 after buying an additional 213 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ZBH shares. Royal Bank Of Canada set a $111.00 price objective on shares of Zimmer Biomet in a research note on Friday, October 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 price target on the stock. Raymond James Financial increased their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Finally, Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Price Performance

NYSE ZBH opened at $101.18 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The company has a fifty day simple moving average of $101.81 and a 200 day simple moving average of $97.63. The company has a market cap of $20.04 billion, a P/E ratio of 24.62, a P/E/G ratio of 2.37 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the firm earned $2.01 EPS. Zimmer Biomet’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet’s dividend payout ratio is 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.